Document:

Amendment to Collaboration and License Agreement

 Exhibit 10.21 
 ***Text Omitted and Filed Separately 
 with the
Securities and Exchange Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 240.24b-2. 
 AMENDMENT TO 
 COLLABORATION AND LICENSE AGREEMENT 
 THIS AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT (the
“Amendment”) is entered into as of October 5, 2009 (the “Amendment Effective Date”) by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation
(“ACADIA”) with offices at 3911 Sorrento Valley Blvd., San Diego, CA 92121, and BIOVAIL LABORATORIES INTERNATIONAL SRL, a Barbados society with restricted liability
(“BLS”), having its registered office at Welches, Christ Church, Barbados WI, BB17154. 
 WHEREAS 
 A. The parties previously entered into that certain Collaboration and
License Agreement, dated May 1, 2009 (the “Agreement”), and capitalized terms that are used but not defined herein shall have the applicable meaning given such terms in the Agreement. 
 B. Pursuant to the Agreement the parties are developing Pimavanserin, a selective 5-HT2A inverse agonist, for the treatment of Parkinson’s disease
psychosis (“PDP”), and other indications, including Alzheimer’s disease psychosis (“ADP”); 
 C. The first Phase III Clinical Trial with Pimavanserin for PDP, ACP-103-012, did not meet its primary endpoint; 
 D. The second Phase III Clinical Trial with Pimavanserin for PDP, ACP-103-014, has a similar design to ACP-103-012 and is currently ongoing; 
 E. The parties wish to amend certain responsibilities under the Agreement, including responsibilities with respect to the PDP and ADP
Indications; and 
 NOW THEREFORE, in consideration of the foregoing and the covenants and
premises contained in this Amendment, the parties hereby agree as follows: 
 PDP Program Continuation 
 1. ACADIA and BLS intend to continue the development of Pimavanserin for PDP, but have agreed to conclude the currently ongoing ACADIA
Study, ACP-103-014 (the “-014 Trial”). For greater certainty, ACADIA shall remain responsible for completing and paying for any tasks associated with concluding the -014 Trial. Based on the results of the ACP-103-012 trial,
the parties are planning the design of a new Phase III Clinical Trial for Pimavanserin in PDP (the “New PDP Trial”), which would be a two-arm study of (i) 40mg of Pimavanserin and (ii) placebo. The PDP Development
Plan (including the Budget included therein) shall be amended to reflect the New PDP Trial, subject to approval of the Development Committee. 
  

 1 

 2. The New PDP Trial shall be an Additional Pre-NDA PDP Study and shall be funded by
BLS in accordance with, and subject to the other terms of, the Agreement including, without limitation, the terms of Section 4.8(a)(i) of the Agreement, to the extent not modified or amended pursuant to this Amendment. Notwithstanding the
foregoing, if, following completion of the New PDP Trial according to the protocol approved by the Development Committee, the Development Committee determines that the results from the New PDP Trial indicate that the 40 mg dose did not meet the
primary end-point set forth in such protocol (the “DC PDP Determination”), then ACADIA shall reimburse BLS for 50% of the Development Expenses incurred in conducting the New PDP Trial that do not exceed the Budget for such
New PDP Trial Expenses by more than [...***...] unless otherwise approved by the Development Committee (the “New PDP Trial Expenses”). BLS shall provide ACADIA with Quarterly Reports contemplated by Section 4.8(b)
for the New PDP Trial for ACADIA’s information and tracking. 
 3. Within [...***...] days after the DC PDP
Determination, BLS shall provide ACADIA with a written report setting forth in reasonable detail the New PDP Trial Expenses (together with the evidence supporting such New PDP Trial Expenses) and setting forth the amount payable by ACADIA to BLS in
accordance with this Amendment. ACADIA shall pay the amount due to BLS within [...***...] days after receipt of the written report. 
 4. For a period of one year following delivery of the written report contemplated by Section 3 of this Amendment from BLS to ACADIA, ACADIA shall have the right to cause an
independent, certified public accounting firm reasonably acceptable to BLS to audit BLS’ records relating to the New PDP Trial Expenses to confirm the amount of the New PDP Trial Expenses reflected in the written report. Such audit right may be
exercised during normal business hours upon reasonable prior written notice. As appropriate, prompt adjustments to payments made pursuant to Section 3 of this Amendment shall be made by the parties to reflect the results of such audit. ACADIA
shall bear the full cost of such audit unless such audit discloses an over-reporting by BLS of more than [...***...] of the amount of New PDP Trial Expenses, in which case BLS shall bear the full cost of such audit. 
 5. Section 4.8(a)(i) of the Agreement shall be amended and restated to read “(i) BLS shall bear 100% of all Development
Expenses, excluding [...***...] Expenses related to the ACADIA Studies (other than that portion of the ACADIA Studies for which the Parties mutually agree to share costs pursuant to the Development Plan and applicable Budget), that do not
exceed the Budget for such Development Expenses by more than [...***...] unless otherwise approved by the Development Committee [...***...]” 
  

 2 
 ***Confidential Treatment Requested 

 6. The lead-in to Section 6.2 of the Agreement shall be amended and restated to
read “Milestone Payments. In further consideration for the licenses and rights granted to BLS hereunder, BLS shall pay to ACADIA the milestone payments set out below following the first achievement of the corresponding milestone. A Party
shall notify the other Party in writing within [...***...] days after the achievement of each milestone event, and ACADIA shall invoice BLS at the time of or following such notice for the applicable milestone payment. BLS shall pay to ACADIA
the amounts set forth below within [...***...] days after its receipt of ACADIA’s invoice. The payments set forth in this Section 6.2 shall not be refundable or creditable against any other payments by BLS to ACADIA under this
Agreement [...***...]” 
 7. The lead-in to Section 4.4(b) of the Agreement shall be amended and restated
to read “Additional Pre-NDA PDP Studies. In the event that the Development Committee determines that [...***...] additional pivotal Phase III Clinical Trials of Product for the prevention or treatment of PDP are required in order
to file an NDA for Product for the prevention or treatment of PDP with the FDA (the “Additional Pre-NDA PDP Studies”), then BLS shall have the option, which it may exercise upon written notice to ACADIA [...***...]
following such determination by the Development Committee, to do one of the following:”. 
 ADP Indication 
 8. Section 4.5(a) of the Agreement provides that the parties will commence an ADP trial with Pimavanserin [...***...].
Section 4.5(a) of the Agreement further provides that BLS shall be responsible for funding such clinical trial under the ADP Development Plan. Notwithstanding Section 4.5(a) of the Agreement, the parties hereby agree that ACADIA may
proceed with a feasibility study for Pimavanserin for the prevention or treatment of ADP (the “ACADIA ADP Trial”) at ACADIA’s sole expense and that the ACADIA ADP Trial shall be deemed to be the
first clinical trial for ADP referenced in Section 4.5 of the Agreement [...***...]. 
 9. The parties
will prepare the ADP Development Plan (including the Budget included therein) to reflect the ACADIA ADP Trial, subject to approval of the Development Committee. The ACADIA ADP Trial shall be conducted according to a protocol agreed to by the parties
and shall be funded by ACADIA and performed by ACADIA in accordance with, and subject to the other terms of, the Agreement. ACADIA shall provide BLS with Quarterly Reports for the New ADP Trial contemplated by for BLS’s information and
tracking.  
  

 3 
 ***Confidential Treatment Requested 

 10. If, following completion of this ADP trial according to the protocol agreed to by
the parties, the Development Committee determines that the results from the ACADIA ADP Trial meet the primary end point for either or both doses being tested (the “DC ADP Determination”), then BLS shall fully reimburse ACADIA
for all of the Development Expenses for the ACADIA ADP Trial that do not exceed the Budget for such Development Expenses by more than [...***...] unless otherwise approved by the Development Committee (the “New ADP Trial
Expenses”). For the avoidance of doubt, following completion of the ACADIA ADP Trial, BLS shall make the election called for by Section 4.5(b) of the Agreement. 
 11. Within [...***...] days after the DC ADP Determination, ACADIA shall provide BLS with a written report setting forth in
reasonable detail the New ADP Trial Expenses (together with the evidence supporting such New ADP Trial Expenses) and setting forth the amount payable by BLS to ACADIA in accordance with this Amendment. BLS shall pay the amount due to ACADIA within
[...***...] days after receipt of the written report. 
 12. For a period of one year following delivery of
the written report contemplated by Section 11 of this Amendment from ACADIA to BLS, BLS shall have the right to cause an independent, certified public accounting firm reasonably acceptable to ACADIA to audit ACADIA’s records relating to
the New ADP Trial Expenses to confirm the amount of the New ADP Trial Expenses reflected in the written report. Such audit right may be exercised during normal business hours upon reasonable prior written notice. As appropriate, prompt adjustments
to payments made pursuant to Section 12 of this Amendment shall be made by the parties to reflect the results of such audit. BLS shall bear the full cost of such audit unless such audit discloses an over-reporting by ACADIA of more than
[...***...] of the amount of New ADP Trial Expenses, in which case ACADIA shall bear the full cost of such audit. 
 General
Provisions 
 13. Full Force and Effect. Except as specifically amended by this Amendment, the Agreement shall
remain in full force and effect. If there is any inconsistency or conflict between any provision in this Amendment and any provision in the Agreement, the provision in this Amendment shall control. 
 14. Miscellaneous. This Amendment may be signed in counterparts, each of which shall be deemed an original, all of which
taken together shall be deemed one instrument. This Amendment and all questions regarding its existence, validity, interpretation, breach or performance of this Amendment, shall be governed by, and construed and enforced in accordance with, the
laws of the State of New York, United States, without reference to its conflicts of law principles with the exception of sections 5-1401 and 5-1402 of New York General Obligations Law. 
  

 4 
 ***Confidential Treatment Requested 

 IN WITNESS WHEREOF, the parties hereto
have duly executed this AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT. 
  

									
	ACADIA PHARMACEUTICALS INC.	  		  	 BIOVAIL LABORATORIES
 INTERNATIONAL SRL

					
	By:	 	 /s/ Uli Hacksell
	  		  	By:	 	 /s/ William M. Wells

	Name:	 	 Uli Hacksell
	  		  	Name:	 	 William M. Wells

	Title:	 	 CEO
	  		  	Title:	 	 PresidentLease Amendment Dated 01/22/2010

 Exhibit 10.25 
 FOURTH AMENDMENT TO LEASE 
 RE TERMINATION
OF LEASE AS TO 3931 SORRENTO 
  

			
	PARTIES:	  	RGH HOLDINGS LIMITED PARTNERSHIP, an Alaskan limited partnership (successor-in-interest to E.G. SIRRAH LLC, a California limited liability company)
		  	P.O. Box 2790
		  	Malibu, California 90265
		  	(“Lessor”)
		
		  	ACADIA PHARMACEUTICALS INC., a Delaware corporation
		  	3911 Sorrento Valley Boulevard
		  	San Diego, California 92121
		  	(“Lessee”)
		
	DATE:	  	January 22, 2010
		
	PLACE:	  	Los Angeles, California

  
  
 RECITALS 

A. Lessor and Lessee are the current parties to a Lease dated August 15, 1997 between R.G. Harris Co. and Harris Family Revocable
Trust, as Lessor, and Receptor Technology, Inc. (the “Original Lease”), as amended by an Amendment No. 1 dated October 30, 1997 (the “First Amendment”), an Amendment No. 2 dated November 1, 2005 (the
“Second Amendment”), and by a Third Amendment to Lease dated November 30, 2007 (the “Third Amendment”) (collectively, the “Lease”), pertaining to premises located at 3911 Sorrento Valley Boulevard (the
“Original Premises” or “3911 Sorrento”) and 3931 Sorrento Valley Boulevard (the “Expansion Space” or “3931 Sorrento”), San Diego, California (collectively, the “Premises”). The Lease provides Lessee
with certain early termination rights as to both the Original Premises and the Expansion Space. 
 B. Lessee has advised Lessor
that Lessee no longer requires the use of 3931 Sorrento, which was added to the Premises by the Third Amendment. 3931 Sorrento is comprised of land improved with a building (the “3931 Building”) of approximately 24,000 rentable square feet
and ninety-six (96) parking spaces on the parking lot adjacent to the 3931 Building. Accordingly, the parties have agreed to terminate the Lease as to 3931 Sorrento only (but not as to 3911 Sorrento) effective as of January 26, 2010, as
well as to reduce the rent for 3911 Sorrento on the terms and conditions set forth in this Fourth Amendment to Lease (the “Fourth Amendment”). 
  

 1 

 THEREFORE, Lessor and Lessee hereby amend the Lease in the following particulars only:

 AGREEMENT 
 1. Termination of Lease as to 3931 Sorrento; Surrender; Security Deposit. Effective as of 11:59 p.m. on January 26, 2010 (the “3931 Sorrento Termination Date”), the Lease is hereby
terminated solely as to 3931 Sorrento (including but not limited to the 96 parking spaces allocated to 3931 Sorrento), but not as to 3911 Sorrento nor the parking spaces allocated to 3911 Sorrento. Such Termination Date shall be treated for all
purposes to be the expiration date of the Lease term as to 3931 Sorrento. The extension options for 3931 Sorrento under Paragraph 9 of the Third Amendment are also hereby deleted from the Lease. Notwithstanding the 3931 Sorrento Termination Date,
Lessee agrees to pay Lessor the monthly rent for 3931 Sorrento through February 28, 2010. Lessee agrees to vacate and surrender to Lessor possession of 3931 Sorrento on or before the 3931 Sorrento Termination Date in the manner and condition
required by Paragraph 7.4 of the Original Lease and other applicable Lease provisions, free of any occupancies, claims to occupancy, liens, Trade Fixtures (as defined in Paragraph 7.3(a) of the Original Lease) or personal property (other than the
cubicles and office furniture to be surrendered with 3931 Sorrento as described below) of Lessee or of any subtenant or other third party claiming under Lessee. If Lessee fails to so surrender 3931 Sorrento by the 3931 SorrentoTermination Date,
Lessor may, in addition to its other remedies, elect in writing in its sole discretion either (i) to defer the 3931 Sorrento Termination Date until 3931 Sorrento is so surrendered, or (ii) to cancel this Fourth Amendment at any time
thereafter until such surrender occurs, by giving written notice of such termination to Lessee. 
 Without limiting the
foregoing, Lessee agrees to leave and surrender 3931 Sorrento broom clean and in the same condition as existed on the Expansion Date (as defined in the Third Amendment), reasonable wear and tear excepted. In addition, Lessee shall surrender to
Lessor at the same time, in “as is” condition, all cubicles and office furniture located in 3931 Sorrento as of the 3931 Sorrento Termination Date. Such cubicles and office furniture shall thereupon become the property of Lessor. The
parties acknowledge that the majority of the cubicles and office furniture was left behind by the prior tenant. Lessee does not have an inventory of the items left by the prior tenant or those owned by Lessee. Lessee accordingly can make no
representation or warranty regarding title to items left behind by the prior tenant or any liens and encumbrances thereon created by the prior tenant or other third parties. However, Lessee warrants to Lessor that none of the cubicles and office
furniture being surrendered by Lessee is subject to liens, encumbrances or other claims against title created by or through Lessee. Lessee hereby provides written confirmation of Lessee’s surrender to Lessor of Lessee’s right, title and
interest to all of the cubicles and office furniture being surrendered by Lessee to Lessor (whether left by the prior tenant or owned by Lessee), consistent with the foregoing provisions. Lessee also agrees to surrender to Lessor with 3931 Sorrento
possession of all keys, security cards, access codes, and alarm controls for 3931 Sorrento, to the extent such items exist. 
  

 2 

 Due to Lessee’s surrender of the 96 parking spaces for 3931 Sorrento on the 3931
Sorrento Termination Date, from and after such date, Lessee and its employees and invitees shall use only those parking areas allocated to the Original Premises at 3911 Sorrento. 
 Within 30 days following the early termination of the Lease as to 3931 Sorrento and Lessee’s surrender of 3931 Sorrento to Lessor,
Lessor shall return to Lessee the $32,520 additional security deposit described in Paragraph 5 of the Third Amendment, less any sums that Lessor is entitled to apply or retain pursuant to Paragraph 5 (“Security Deposit”) of the Original
Lease. Lessor shall continue to hold the Security Deposit attributable to 3911 Sorrento as described in Paragraph 5 of the Original Lease and Section 15 of the Second Amendment. 
 2. Exit Assessment; Lessor’s Access to 3931 Sorrento. Without limiting Lessor’s rights under Paragraphs 6 and 7 of the
Original Lease or other provisions of the Lease, as amended by this Fourth Amendment, Lessee, at Lessee’s sole cost and expense, shall cause to be conducted on or before the 3931 Sorrento Termination Date, a preliminary environmental site
assessment by Occupational Services, Inc. of San Diego, California (or another qualified consultant pre-approved in writing by Lessor) with respect to the existence of Hazardous Substances (as defined in Paragraph 6 of the Original Lease) on or
about 3931 Sorrento, and shall promptly provide to Lessor a copy of such consultant’s written report. Such report may, at Lessee’s election, be done by Occupational Services, Inc. as an update to its report dated November 9, 2007,
regarding 3931 Sorrento, which was prepared pursuant to Section 8 of the Third Amendment. Lessee’s obligations regarding Hazardous Substances as set forth in Paragraph 6.2 of the Original Lease shall survive the termination of the Lease as
to 3931 Sorrento (as well as any later expiration or termination of the Lease as to 3911 Sorrento). 
 3.
Representations. In connection with the early termination of this Lease as to 3931 Sorrento, Lessee represents that it has not made, and will not make, any assignment, sublease, transfer, conveyance, encumbrance, or other disposition of the
Lease, or any interest in the Lease, as it relates to 3931 Sorrento, or of any claim, demand, obligation, liability, or cause of action arising from the Lease as it relates to 3931 Sorrento (collectively, “Claims” as used in this Paragraph
3). 
  

 3 

 4. Base Rent for Original Premises. Effective January 1, 2010, the Base Rents
for the Original Premises shall be reduced by 20% from the amounts set forth in Paragraph 4 of the Second Amendment and Paragraph 4.2 of the Third Amendment. Accordingly, the Base Rents for the Original Premises (on a “triple-net” basis)
for the period from January 1, 2010, through December 31, 2012, shall be as follows: 
  

										
	 Period of Time
	    	Prior Scheduled Monthly
Base Rent For Original
Premises Per Lease	    	Monthly Base
Rent Credit
	    	Remaining Monthly
Base Rent for Original
Premises after Credit
	1/1/10-10/31/10	    	$	63,428.05	    	$	12,685.61	    	$	50,742.44
	11/01/10-10/31/11	    	$	65,330.89	    	$	13,066.18	    	$	52,264.71
	11/01/11-10/31/12	    	$	67,290.82	    	$	13,458.16	    	$	53,832.66
	11/01/12-12/31/12	    	$	69,309.54	    	$	13,861.91	    	$	55,447.63

 In addition to
the foregoing Base Rents for 3911 Sorrento, up until February 28, 2010, Lessee shall also pay the Base Rent for 3931 Sorrento (presently $29,280.84 per month) as set forth in Paragraph 4.3 of the Third Amendment. 
 The reduced Base Rents set forth in this Paragraph 4 are in addition to, not in lieu of, the charges described in the Lease other than Base
Rent for 3911 Sorrento (and for 3931 Sorrento, for the period up until February 28, 2010). Such other charges for which Lessee shall remain liable include, but are not limited to (i) Lessee’s obligations for Real Property Taxes,
insurance premiums, utility costs and other operating expenses of the Premises and the Project, and (ii) any “Amortization Rent” under Paragraph 5 of the Second Amendment. 
 5. Lessee’s Share of Expenses. In order to reflect the deletion of 3931 Sorrento from the Premises, with respect to the period
from and after February 28, 2010, Lessee’s share of Real Property Taxes, insurance premiums, utility costs and other operating expenses for the Project (which consists of 3911 Sorrento and 3931 Sorrento) shall be determined without regard
to Paragraph 4.4 of the Third Amendment (which allocated to Lessee the expenses attributable to 3931 Sorrento). Accordingly, for the period from and after the February 28, 2010, Lessee’s share of such items shall be governed by the
provisions of the Original Lease as amended by the First Amendment and the Second Amendment, and shall be reasonably calculated by Lessor based upon the percentage that the gross leasable area of the 3911 Sorrento building comprises of the total
gross leasable area of the buildings in the Project (or on such other basis as is provided for a particular expense item in the Original Lease as amended by the First Amendment and the Second Amendment). Without limiting the foregoing, Lessee shall
continue to pay all of the Real Property Taxes and other expenses attributable to that portion of the parking area at the Project allocated to 3911 Sorrento. 
  

 4 

 The termination of the Lease as to 3931 Sorrento shall not release Lessee from its
obligations for any such expense items attributable to the period up through February 28, 2010, regardless of whether such items are first billed after that date. Such items for calendar year 2010 shall be equitably prorated, as calculated by
Lessor in its reasonable discretion, to reflect the deletion of 3931 Sorrento from the Premises for purposes of such expenses as of that date. 
 6. Increased Termination Fee for Termination of Lease as to Original Premises. In consideration of this Fourth Amendment to Lease, and notwithstanding anything to the contrary in the Lease, if the
Lease is terminated early as to the Original Premises (3911 Sorrento) pursuant to Paragraph 13A of the Second Amendment, Lessee shall pay a termination fee to Lessor equal to the Termination Fee described in Paragraph 13A of the Second Amendment
plus the sum of $34,941.00 (collectively, the “Increased Termination Fee”). As of the effective date of this Fourth Amendment, references in the Second Amendment and Third Amendment to the Termination Fee shall mean the Increased
Termination Fee described above in this Paragraph 6. 
 7. Releases. Lessee shall remain obligated to perform all of its
obligations as to 3931 Sorrento under the Lease, as amended to date, attributable to the period up through the 3931 Sorrento Termination Date and Lessee’s surrender to Lessor of 3931 Sorrento. Subject to Lessee’s performance of its
obligations under this Fourth Amendment attributable to 3931 Sorrento, Lessee shall be released from its obligations under the Lease as to 3931 Sorrento arising during and attributable to the period after the 3931 Sorrento Termination Date and
Lessee’s surrender to Lessor of 3931 Sorrento. Such release shall not apply to Lessee’s obligations under the Lease as to 3911 Sorrento. Similary, such release shall not apply to any obligations of Lessee under this Fourth Amendment, nor
to any obligations of Lessee under the Lease as to 3931 Sorrento arising during or attributable to the period up through the 3931 Sorrento Termination Date and Lessee’s surrender to Lessor of 3931 Sorrento (such as (a) any taxes, insurance
premiums, utility costs, and other expense items for 3931 Sorrento attributable to such period (and up through February 28, 2010, as described in Paragraph 5), regardless of whether they are first billed thereafter; and (b) any obligations
of Lessee to indemnify, defend, or hold harmless Lessor pursuant to the Lease). 
 8. Prorated Brokerage Commissions. The
parties acknowledge that no brokers represent either party in this transaction, except in connection with the application of Paragraph 10 of the Third Amendment (under which CB Richard Ellis, Inc., acting through Jerry Keeney, was designated as
Lessor’s Broker, and Irving Hughes, acting through Shaun Burnett, was designated as Lessee’s Broker, in connection with the prior addition of 3931 Sorrento to the Premises). As required by Paragraph 10 of the Third Amendment, due to the
early termination of the Lease as to 3931 Sorrento, the Additional Commission (as defined in such Paragraph 10 of the Third Amendment) shall be equitably prorated to reflect only the portion of the extended Original Term up

  

 5 

 
through the 3931 Sorrento Termination Date. Except as provided in the preceding two sentences, if Lessee has dealt with any real estate broker or other person or firm with respect to this Fourth
Amendment, Lessee shall be solely responsible for the payment of any fee due such broker, person or firm, and Lessee hereby agrees to indemnify, defend and hold Lessor harmless from and against any claim, liability or expense with respect thereto.
Except as provided in this Paragraph 8, if Lessor has dealt with any real estate broker or other person or firm with respect to this Fourth Amendment, Lessor shall be solely responsible for the payment of any fee due such broker, person or firm, and
Lessor hereby agrees to indemnify, defend and hold Lessee harmless from and against any claim, liability or expense with respect thereto. Except as provided above in this Paragraph 8, Lessor shall not be responsible for any compensation to any
brokers for their services rendered in this transaction. 
 9. Miscellaneous. This Fourth Amendment supersedes all prior
or contemporaneous understandings, negotiations, or agreements between the parties, whether written or oral, with respect to its subject matter. This Fourth Amendment is part of and shall be attached as an addendum to the Lease. The Lease, as
amended by this Fourth Amendment, may be further amended only in a writing signed by both Lessor and Lessee. All terms of the Lease which have not been expressly altered by this Fourth Amendment shall remain in full force and effect. In the event of
any litigation or other proceeding between the parties (including for this purpose, but not limited to, Lessor’s Broker or Lessee’s Broker, as such terms are defined in the Third Amendment) arising out of or relating to this Fourth
Amendment, the prevailing party shall be entitled to recover from the losing party the prevailing party’s reasonable attorney fees and costs of suit, all as further provided in Paragraph 31 of the Original Lease. 
 10. Execution in Counterparts; Electronic Signatures. This Fourth Amendment to Lease may be executed in counterparts by the parties,
and when each party (including Lessor’s Broker and Lessee’s Broker) has signed and delivered at least one such counterpart, each counterpart shall be deemed an original, and, when taken together with other signed counterparts, shall
constitute one agreement, which shall be binding upon and effective as to all parties. Each party shall be bound by signatures transmitted by facsimile or e-mail in the same fashion as such party would be bound by original signatures. Any party
delivering signatures by facsimile or e-mail transmission shall, for convenience and record-keeping purposes, provide original signatures to the other parties within 10 days after such party binds itself by facsimile or e-mail signatures.

  

 6 

 IN WITNESS WHEREOF, the parties have executed this Fourth Amendment to Lease as of the date
and at the place first written above. 
  

							
	LESSEE:	  		  	 ACADIA PHARMACEUTICALS INC.,
 a Delaware corporation

				
		  		  	By:	 	 /s/ Thomas H. Aasen

		  		  	Name:	 	Thomas H. Aasen
		  		  	Title:	 	VP & CFO
			
	LESSOR:	  		  	 RGH HOLDINGS LIMITED PARTNERSHIP,
 an Alaskan limited partnership

							
				
		  		  	By:	 	 /s/ Henry S. Workman

		  		  		 	Its: General Partner

 The undersigned
Brokers are executing this Fourth Amendment to Lease solely to confirm their agreement to Paragraph 8 (“Prorated Brokerage Commissions”) and the last sentence of Paragraph 9 (regarding attorney fees relating to a dispute). 
  

					
	LESSEE’S BROKER:	 		  	IRVING HUGHES

							
				
		 		  	By:	 	 /s/ Shaun Burnett

		 		  		 	                    , Its Senior Vice President

					
			
	LESSOR’S BROKER:	 		  	CB RICHARD ELLIS, INC.

							
				
		 		  	By:	 	 /s/ Jerry Keeney

		 		  		 	                    , Its SVP

  

 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]